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I n d u c t i o n o f t o l e r a n c e t o a l l o g e n e i c M H C a n t i g e n s 
h a s b e e n a g o a l i n t h e f i e l d o f t r a n s p l a n t a t i o n b e c a u s e 
i t w o u l d r e d u c e o r e l i m i n a t e t h e n e e d f o r g e n e r a l i z e d 
i m m u n o s u p p r e s s i o n . A l t h o u g h e n c o u r a g i n g r e s u l t s 
h a v e b e e n o b t a i n e d i n e x p e r i m e n t a l m o d e l s b y e x p o s -
i n g r e c i p i e n t t h y m u s t o d o n o r c e l l s b e f o r e t r a n s p l a n -
t a t i o n , d o n o r c e l l s a r e n o t t y p i c a l l y a v a i l a b l e at t h a t 
t i m e , a n d t h e d o n o r a n t i g e n s r e s p o n s i b l e f o r t h e effect 
a r e p o o r l y d e f i n e d . I n t h e p r e s e n t s t u d y , t h y m i c t o l e r -
a n c e w a s d e m o n s t r a t e d w i t h o u t u s i n g d o n o r c e l l s . R e -
c i p i e n t t h y m u s w a s i n j e c t e d b e f o r e t r a n s p l a n t a t i o n 
w i t h a u t o l o g o u s m y o b l a s t s a n d m y o t u b e s t h a t w e r e 
g e n e t i c a l l y m o d i f i e d t o e x p r e s s a l l o g e n e i c d o n o r - t y p e 
M H C c l a s s I a n t i g e n . D o n o r - s p e c i f i c u n r e s p o n s i v e n e s s 
w a s i n d u c e d t o a c o m p l e t e l y M H C - d i s p a r a t e l i v e r 
t r a n s p l a n t a n d t o a s u b s e q u e n t d o n o r - t y p e c a r d i a c a l -
l o g r a f t , b u t n o t a t h i r d - p a r t y a l l o g r a f t . I n v i t r o , r e c i p i -
e n t C T L d e m o n s t r a t e d a 10-fold r e d u c t i o n i n k i l l i n g o f 
d o n o r c e l l s , b u t n o t o f t h i r d - p a r t y c e l l s . O u r r e s u l t s 
d e m o n s t r a t e : (1) t h a t r e c i p i e n t m u s c l e c e l l s c a n b e ge-
n e t i c a l l y e n g i n e e r e d t o i n d u c e d o n o r - s p e c i f i c u n r e -
s p o n s i v e n e s s w h e n g i v e n i n t r a t h y m i c a l l y , a n d (2) 
t r a n s f e c t e d r e c i p i e n t c e l l s e x p r e s s i n g o n l y d o n o r M H C 
c l a s s I a n t i g e n c a n i n d u c e t o l e r a n c e t o a f u l l y a l l o g e -
n e i c d o n o r . 
Tolerance to self-MHC antigens normally develops via pre-
sentation of these antigens on thymic epithelium (2). Thy-
mocytes responsive to self-MHC undergo apoptosis resulting 
in antigen-induced tolerance (2, 3). Application of this strat-
egy to tolerance induction in an adult animal transplant 
model was described by Posselt et al. (4), who injected mu-
rine islets intrathymically to permit donor-specific unrespon-
siveness to subsequent islet cell transplants. Their group 
obtained similar results by injecting bone marrow cells 
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rather than islets into thymus (5), suggesting that thymic 
exposure to donor alloantigen is necessary to promote toler-
ance. Similar results have been obtained by Goss et al. (6) 
using a rat heart transplant model and intrathymic injection 
of donor splenocytes. Remuzzi et al. (7) prolonged renal 
transplant survival by intrathymic injection of glomeruli, 
showing that parenchymal cells can also induce thymic tol-
erance. Thymic tolerance models in rodents have required 
thymic exposure to alloantigen near the time of transplanta-
tion and concomitant lymphoablative therapy using antilym-
phocyte serum (ALS)* (8) or irradiation (9). 
In most transplant models of thymic tolerance, thymic ex-
posure to donor cells has occurred several days or weeks 
before organ transplantation (4-7). This approach has lim-
ited clinical potential because of the absence of appropriate 
donor cells before donor organ availability. More importantly, 
it is not known which donor antigens are necessary or suffi-
cient for tolerance induction. In the present study, we have 
used a strategy for producing thymic tolerance in a rat model 
that avoids the requirement of donor cells and allows the 
study of individual donor antigens using genetically altered 
recipient cells. We demonstrate the efficacy of intrathymic 
administration of autologous plasmid-transfected myoblasts 
(MB) and myotubes (MT) expressing donor M H C class I an-
tigen to induce donor-specific unresponsiveness after liver 
transplantation in a fully allogeneic, high responder, rat 
strain combination. Using genetic manipulation, we show a 
tolerogenic effect with only M H C class I antigen. 
MATERIALS AND METHODS 
Preparation of the primary cell cultures. Primary muscle cell cul-
tures were prepared as reported previously (10, 11). Briefly, minced 
soleus muscles from baby Lewis rats (3-5 days old) were dissociated 
in 0.17% trypsin and 0.09% collagenase in HBSS (pH 7.4, Gibco BRL, 
Gaithersburg, MD) for 55 min in an incubator-shaker at 37°C. After 
centrifuging, the dissociated cells were resuspended in 3 ml of com-
* Abbreviations: ALS, antilymphocyte serum; MB, myoblast; MT, 
myotube; MN4-91-6, murine mAb specific for RTl.A 8; pRSVL, plas-
mid DNA encoding luciferase; pRSVLacZ, plasmid DNA encoding 
Escherichia coli /3-galactosidase; pcRT.45, plasmid DNA encoding rat 
MHC class I RTl.A 8; WF, Wistar Furth. 

plete media (containing 5% chick embryo extract [Gibco BRL], 15% 
horse serum, and 80% modified Eagle's media). MB were purified on 
a Percoll (Sigma Chemical, St. Louis, MO) gradient (20/60X) and 106 
cells were placed into individual 35-mm gelatinized culture plates. 
The cells were then maintained in an incubator (37°C, humidified 
atmosphere of 5% C0 2 in air) with complete media that was changed 
every other day. After 4 days in culture, the cells spontaneously 
began to form MT that matured by 8 days in culture. 
Plasmids and gene transfer procedures. Control plasmids used 
were-plasmid DNA encoding the firefly (Photinus pyraiis) luciferase 
gene (pRSVL) (12) and plasmid DNA encoding Escherichia coli 0-
galactosidase (pRSVLac-Z) (13), under the control of the Rous sar-
coma virus (RSV) long terminal repeat promoter. Plasmid DNA was 
purified by alkaline lysis, banded 2 times in a cesium chloride-
ethidium bromide gradient, dialyzed, and precipitated with ethanol 
before use. 
The cDNA encoding the rat MHC class I antigen RTl.A a (14) was 
placed in a pcDNAl plasmid expression vector (pcRT.45) (15). The 
human immediate early CMV promoter and SV40 poly A and intron 
were used to enhance expression. 
Both 2-day-old cultures containing MB and 4-day-old cultures con-
taining MT were transfected as described previously (10). Briefly, 
plasmid DNA and Lipofectin reagent (Gibco BRL) (16) were diluted 
separately into 0.75 ml of Opti-MEM I reduced-serum medium 
(Gibco BRL). The 2 solutions were then mixed together drop by drop 
in a polystyrene tube. The DNA-Lipofectin complex solution was 
added to the primary muscle cells, which had been washed 3 times 
with Opti-MEM. After a 4-hr incubation, 1 ml of complete medium 
was added to each plate. Transfection plates were then maintained in 
the incubator at 37°C, 5% C0 2 . 
Intrathymic transplantation. One day after DNA transfection, the 
MB and MT were harvested using Cell Lifters (Fisher Scientific, 
Pittsburgh, PA). Five plates of the 3-day-old MB cultures were mixed 
with 5 plates of the 8-day-old MT cultures in a volume of 0.2 ml 
containing approximately 107 cells for implantation into 1 recipient 
animal. The MT formed large rounded cells in suspension that were 
easily counted using a hemocytometer. Lewis rats were anesthetized 
by intramuscular ketamine (70 mg/kg) and xylazine (6 mg/kg). A 
small skin incision was made along the anterior midline at the base 
of the neck. The upper part of the thymus was exposed by opening 
the upper sternum in the midline. The genetically modified muscle 
cells harvested from 10 plates were injected in equal proportions into 
both lobes of the thymus using a 1.0-ml syringe with a 27-gauge 
needle. The rat simultaneously received 0.8 ml of ALS (specific for rat 
lymphocytes; Accurate Chemical & Scientific Corp., Westbury, NY) 
intraperitoneally. Controls received no ALS. 
Detection of transgene expression in cultured muscle cells. Flow 
cytometry was used to detect RTl.A 3 expression on pcRT.45-trans-
fected myocytes. Cells were first reacted for 30 min at 4°C with either 
isotype-control antibody (mouse IgGl, Becton Dickinson, San Jose, 
CA) or mouse anti-rat RTl.A 3 specific antibody (MN4-91-6; Byprod-
ucts for Science, Indianapolis, IN). Cells were washed 2 times with 
PBS and then were reacted for 30 min at 4°C with goat anti-rat 
IgG-FITC (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA). Cells were washed 2 times with PBS, and were analyzed 
by flow cytometry. 
Histochemistry. For evaluation of morphologic changes in trans-
planted hearts and livers, paraffin sections were stained with 
Mayer's hematoxylin and eosin. 
Cultured MT transfected with pcRT.45 or with control pRSVLacZ 
were stained immunohistochemically. Cells were fixed with 2% 
paraformaldehyde in PBS, and were incubated with MN4-91-6 
(1:200) overnight at 4°C. A biotinylated goat anti-mouse IgG anti-
body and avidin-conjugated horseradish peroxidase complex (Vector 
Laboratories, Inc., Burlingame, CA) were used to reveal MN4-91-6 
binding. Substrate was converted to product by 3-amino-9-ethylcar-
bazole (Sigma). 
Immunofluorescent staining was performed on 10-um cryostat 
thymus sections. Sections were incubated overnight at 4°C with a 
mixture of 2 primary antibodies: (Da rabbit anti-myosin antibody 
(1:20, Sigma), and (2) MN4-91-6 (1:200) for double-labeling the 
muscle cells expressing RTl.A 3 . The sections were incubated with a 
mixture of fluorescence-conjugated secondary antibodies for 3 hr at 
room temperature. Myocytes were visualized with goat anti-rabbit 
IgG-FITC (1:100, Jackson ImmunoResearch) and the RTl.A 3 protein 
was visualized with goat anti-mouse IgG-Texas Red (1:100, Jackson 
ImmunoResearch). 
Liver transplantation. Three weeks after thymic transfer of trans-
genic cells, OLT were performed from male ACI rat donors to male 
Lewis rat recipients using a technique described previously (17). 
This strain combination was chosen because it normally results in 
rigorous rejection of the transplanted liver, since the ACI strain is a 
strong stimulator and the Lewis strain is a strong responder im-
munologically. The time of rejection was defined by death of the 
recipient, and rejection was confirmed by histologic examination of 
the liver. Rats were obtained from Harlan Sprague-Dawley (India-
napolis, IN) and were cared for according to standard NIH guide-
lines. 
Limiting dilution analysis. Twelve replicate cultures containing 
limiting numbers of Lewis cervical lymph node cells from 3 animals 
surviving transplant were cocultured with 5xl0 4 irradiated (2000 
rads) ACI or third-party Wistar Furth (WF) splenic stimulator cells 
per well, as described previously (18). After 7 days, 104 51Cr-labeled 
con A-stimulated ACI or third-party splenocytes were added, and 
5 1 Cr release was measured after a 5-hr incubation. Wells with cpm 
values > 3 SD above the mean spontaneous 5 1 Cr release were scored 
as positive. The frequency of CTL precursors was calculated as de-
scribed previously by Derry and Miller (19). 
RESULTS 
Transgenic MHC class I antigen expression. Approximately 
13-30% of primary cultured Lewis rat M B and M T trans-
fected with pcRT.45 (plasmid encoding RTl .A 3 ) tested posi-
tive for R T l . A 3 surface antigen 48 hr after lipofection, as 
measured by flow cytometry (Fig. 1), and by inspection of cell 
cultures using immunohistochemistry (Fig. 2, A and B). One 
week after intrathymic injection of pcRT.45-transfected 
mixed M B and M T (MB/MT), the presence of skeletal muscle 
cells expressing R T l . A 3 in the Lewis rat thymus was demon-
strated by double-labeling myocytes with antibodies specific 
for R T l . A 3 and myosin (Fig. 3). Myosin-specific staining of 
the thymus 1 week after implantation confirmed the pres-
ence of myocytes containing myosin and myofilaments (Fig. 
3, A, C, and E). Myocytes were observed throughout the thy-
mus, and some expressed R T l . A 3 (Fig. 3, B, D, and F). 
Intrathymic myocyte transfer and liver allograft survival. 
Lewis ( R T l . A B W C 1 ) recipients underwent orthotopic ACI 
(RT1.A 3 B 3 D 3 C 3 ) liver transplants 3 weeks after intrathymic 
injection of 107 pcRT.45-transfected Lewis MB/MT. Survival 
times of the recipients were measured with and without A L S 
treatment (Table 1). The rats receiving no intrathymic injec-
tions survived approximately 10-11 days with or without 
ALS. Thymic injection of M B / M T expressing reporter genes 
prolonged survival in 5 of 7 recipients treated with ALS, 
although all 5 recipients eventually died with rejection. Re-
cipients injected intrathymically with pcRT.45-transfected 
MB/MT, but not receiving ALS, showed a slight prolongation 
of graft survival to a median of 15 days. Rats receiving 
pcRT.45-transfected M B / M T intrathymically, as well as A L S 
intraperitoneally, showed marked prolongation of survival. 
Three long-term survivors of the tolerogenic protocol re-
ceived both ACI and third-party WF (RT1.A U B U D U C U ) heart 
Fluorescence Intensity 
FIGURE 1. Cultured MB and MT transfected with pcRT.45 were analyzed for R T l A a expression by flow cytometry after 48 hr. A and C 
represent transfected MB and MT, respectively, reacted with isotype-control antibody. In B, the same MB were reacted with RTl.A 8 antibody 
(MN4-91-6); D shows the histogram for the MT reacted with MN4-91-6. In the experiment shown, 11% of the MB were positive and MT were 
13% positive. 
transplants at least 60 days after their liver transplant with-
out any additional immunosuppression. One heart was 
placed intra-abdominally, and the other anastomosed to the 
femoral vessels in the groin. In 2 cases, the ACI heart trans-
plants survived indefinitely (> 100 days) without rejection, 
while the third-party WF hearts were rejected at 8 and 10 
days. The third rat died 10 days after heart transplantation 
for technical reasons, but had rejected the WF heart at 8 days 
and the ACI heart was still beating just before death. 
Histologic examination of multiple sections of ACI livers 
and hearts transplanted to tolerized Lewis recipients dem-
onstrated no evidence of rejection at the time of death, which 
was > 100 days after transplantation. Third-party WF hearts 
underwent acute cellular rejection with a prominent lympho-
cytic infiltrate seen histologically. 
Cytotoxic T cell frequency analysis. Compared with the nor-
mal Lewis rat response to ACI stimulators and targets, the 
tolerant Lewis rats demonstrated a markedly diminished 
C T L precursor frequency for ACI targets (Fig. 4A), yet they 
maintained a normal C T L precursor frequency against third-
party W F targets (Fig. 4B). The mean ± SD frequency of 
ACI-specific C T L precursors in the 3 experiments with nor-
mal Lewis controls was 1 /1 ,995±609 , and 1/12,081 ± 3 , 5 2 6 
with the tolerized group. The effect was donor-specific, since 
the C T L precursor frequency against third-party WF targets 
was l / 3 , 7 7 0 ± 2 , 0 4 5 with Lewis controls, and 1/4,001± 1,930 
with the tolerized group. 
Routes of transfected myocyte administration. Controls 
were used to determine the importance of the site of delivery 
of the R T l . A a antigen via transfected MB/MT. Intravenous or 
intraperitoneal administration of pcRT.45-transfected Lewis 
M B / M T at the same doses as used for intrathymic injection 
did not alter graft survival, even with concomitant A L S treat-
ment (Table 2). 
DISCUSSION 
Specific tolerance in adults has been achieved in rodent 
models by intrathymic administration of donor lymphoid 
cells or parenchymal cells in the setting of A L S treatment 
(4-8). Thymic exposure to allogeneic donor cells permits pre-
sentation of alloantigen to maturing thymocytes, mimicking 
the normal developmental process, and resulting in unre-
sponsiveness or deletion of T cell clones specific for donor 
alloantigen. Transgenic cells expressing the putative donor 
M H C antigen necessary for tolerance induction would pro-
vide a useful alternative to donor cells. Madsen et al. (20) 
reported the potential usefulness of intravenous administra-
tion of cells from a cultured fibroblast cell line transgenically 
expressing allo-MHC for inducing immunologic unrespon-
siveness. Recently, donor-type M H C class II allopeptides in-
FIGURE 2. Primary cultures of Lewis rat 
MT; RTl.Aa-specific mAb MN4-91-6 stained 
pcRT.45-transfected MT (A), but not the pRSV-
LacZ-transfected control MT (B). 
jected intrathymically have also been shown to promote sys-
temic tolerance to subsequent renal allografts (21). 
In the present study, we achieved tolerance using primary 
cultured autologous cells expressing only allogeneic M H C 
class I antigen, and not M H C class II or non-MHC antigens. 
The results demonstrate that marked prolongation of graft 
survival, and in some cases donor-specific tolerance, is ob-
tainable with a limited repertoire of donor antigens (only one) 
in a highly disparate rat strain combination. In fact, the 
strain combination was chosen specifically because it is a 
high-responder combination normally resulting in vigorous 
liver transplant rejection. Tolerance in this model was donor 
specific, as demonstrated by the results of the in vitro limit-
ing dilution assay showing marked reduction in C T L precur-
sor specific for ACI donor cells. Furthermore, the subsequent 
acceptance of the tolerized donor-strain heart transplant and 
rejection of the third-party donor heart transplant demon-
strates in vivo evidence of donor-specific tolerance. The in 
vitro results were consistent with these, suggesting that the 
mechanism of thymic unresponsiveness in this model is due 
at least in part to a decrease in C T L responsiveness to the 
donor. 
It is notable that intrathymic injection of M B / M T express-
ing only the reporter gene prolonged survival in a few ani-
mals. This effect might have been due to the nonspecific 
influence of thymic injection, since Staples et al. (9) demon-
strated that injection of bovine 7-globulin into rat thymus 
results in depressed immunity to subsequent skin grafts. 
The role of the thymus appears to be central. Transgenic 
cells administered intravenously or intraperitoneally were 
not effective at inducing tolerance, demonstrating the supe-
riority of the thymic route. The form of the antigen expressed 
FIGURE 3. Micrographs of the thymus sections using double immunofluorescence show implanted myocytes (a, c, and e) and myocytes 
expressing RTl.A" (b, d, and f). Closed arrows indicate double-labeled muscle cells; open arrows indicate muscle cells labeled only with 
anti-myosin. Scale bars = 30 um. 
TABLE 1. Survival of ACI to Lewis liver transplant recipients (days) 
Group Intrathymic injection 
Survival (days) (mean ± SD) 
P° 
-ALS +ALS 
1 None 9, 10, 10, 10, 11 10, 11, 11, 14 0.13 vs. 1-
(10±0.7) (11.5+1.7) 
2 MB/MT with pRSVLux 9, 10, 12, 14 10, 12, 18, 23, 24, 25, 75 0.02 vs. 2-
or pRSVLacZ (11.3±2.2) (26.7±22) 0.03 vs. 1 + 
3 MB/MT with pcRT.45 13, 15, 15, 18 13, 14, 18, 18, 44, 56, 72, 74, (76),'' 80, 0.003 vs. 3-
(15.3±2.1) 91, >100, 121, (164),'' (304)* 0.02 vs. 2 + 
(83 ±75) 
0 Log rank survival analysis compared by chi-square tests. 
* Parentheses indicate the rat was killed. 
by transgenic cells may also be a factor. Behara et al. (22) 
have reported that thymic implantation of genetically modi-
fied fibroblasts do not lead to tolerization toward a soluble 
gene product (growth hormone). Failure to induce tolerance 
after thymic exposure to genetically modified fibroblasts may 
have been related to the level of gene expression in the thy-
mus or the soluble nature of the gene product, since both of 
these parameters influence immune responsiveness. 
The role of the liver transplant in testing tolerance induc-
tion with M H C class I antigen in this model may be substan-
tial for 3 reasons. First, unresponsiveness to liver trans-
plants is usually easier to achieve than unresponsiveness to 
either cardiac or renal transplants. For example, rat liver 
transplants can be substantially prolonged by intravenously 
administering blood cells expressing donor M H C class I an-
tigen, whereas cardiac allograft survival is not prolonged by 
the same protocol (23). Second, M H C class I antigen may be 
more important for tolerance induction in liver transplant 
models (24) than in other organ models. Third, the accep-
tance of ACI cardiac allografts after ACI liver transplantation 
may be due in part to a tolerogenic effect of the transplanted 
liver. This phenomenon has been reported in a low-responder 
strain combination (25), although the mechanism is un-
known. 
Gene transfer to autologous cells provides a method to 
study the role of specific gene products in thymic tolerance 
without the interference of other donor antigens. Specific 
immunologic unresponsiveness to a fully MHC-disparate 
liver following presentation of only donor M H C class I in the 
thymus suggests that if manipulation of the recipient im-
mune response favors unresponsiveness rather than rejec-
tion of one important target antigen, other existing M H C and 
FIGURE 4. CTL precursor frequency was assessed in Lewis recipients of ACI liver allografts pretreated with ALS and intrathymic Lewis 
myocytes expressing RTl.A 3 . Experiment shown is representative of three. Cervical lymph node CTL precursor frequency was assessed in 
a normal Lewis control (open circles, dashed lines), and an ALS/myocyte-pretreated Lewis recipient of an ACI liver allograft 60 days after 
transplant (open triangles, solid lines) using (A) ACI or (B) third-party W F splenocyte stimulators and targets. The CTL precursor frequency 
for respective targets is shown on each graph. 
Route 
TABLE 2. Survival of ACI to Lewis liver transplant recipients 
3 weeks after transgene administration intravenously or 
intraperitoneally with ALS 0.8 ml i.p. 
Survival 
(days) 
Intraperitoneal injection MB/MT with pcRT.45 9, 10, 12, 14 
Intravenous injection MB/MT with pcRT.45 10, 11, 13, 17 
non-MHC disparities may be ignored by the recipient im-
mune system and will not necessarily eventuate in rejection. 
A biological approach to tolerance may therefore be feasible if 
the most important, rather than all, of the antigenic dispari-
ties between donor and recipient are addressed. Which anti-
gens are most important may vary according to the organ 
transplanted, with our data suggesting an important role of 
M H C class I in liver transplantation, consistent with results 
in clinical transplantation (26). The important role of M H C 
class II antigens in renal transplant rejection (27) is paral-
leled by the finding that thymic presentation of donor M H C 
class II peptides prolongs subsequent renal allografts in rats 
(21). 
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